Reading Time: 7 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 5 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 5 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 6 minutesWeight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 4 minutesHello everyone. My name is Genevieve (Gen) and I have joined the Association as Philanthropy Information Officer. One of my roles is to communicate the
Reading Time: 5 minutesHi, I’m Ben, a researcher working at Sheffield University. I attended last year’s International Symposium on ALS/MND as one of the Symposium Communication Ambassadors and
Reading Time: 7 minutesHi, I’m Heather, a PhD student from King’s College London, and a Communications Ambassador for the 34th International Symposium on ALS/MND which was held in Basel last December. Over 1,300 attendees from around the world gathered to connect with researchers and people affected by MND and engage with the latest research presented in the platform presentation and poster sessions. In this blog post, I will be sharing several of my personal highlights of the symposium, which cover how differences in our genetic code can be explored to understand their effects on MND risk and progression.
Reading Time: 5 minutes"New drug reduces risk of death by 50%"
You may have seen this type of headline in news articles reporting on the outcome of clinical trials. Reading this headline can lead people to believe a potential drug is highly beneficial and has a real impact. However, it is important to delve a little deeper into the meaning of ‘risk of death’, the raw data behind it, and how it should be considered alongside other outcome measures of a trial to fully determine how effective a drug might be.
Reading Time: 4 minutesIn our brains, specific areas control the movement of different body parts (see image below). As we know, MND is a complex disease with a lot of variation between individuals who are affected. For example, symptoms may start in different body parts for different individuals. Understanding why this happens may help us predict the disease onset site or progression across the body in the future.
34th Symposium: Basel Causes and disease mechanisms Markers of Disease Progression MND Research Symposium
Developing a potential microRNA blood test for ALS diagnosis
Reading Time: 4 minutesI’m Hannah, a PhD student from the University of Nottingham, and a Communications Ambassador for the 34th International Symposium on ALS/MND that took place in